晚期NSCLC组织RRM1的表达及与吉西他滨化疗敏感性的研究

Investigation about expression of RRM1(ribonucleotide reductase M1)and the correlation with Gemcitabine-based che-motherapy sensitivity in the advanced non-small cell lung cancer

目的探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中核糖核苷酸还原酶M1(ribonu-cleotide reductase M1,RRM1)的表达及其与吉西他滨化疗敏感性的关系。方法收集2005年1月-2008年12月在本科室经病理组织学诊断的用含吉西他滨方案化疗的晚期(Ⅲb、Ⅳ期)NSCLC患者的病理标本51例,采用免疫组化方法检测RRM1的表达情况,并分析RRM1表达与患者近期疗效及中位疾病进展时间(Time to Progression,TTP)的关系。样本率的比较用检验;用Kaplan-meier法对TTP进行单因素生存分析,并采用Log-rank法检验。结果RRM1表达阳性率为33.3%(17/51),化疗有效率为17.65%,阴性组化疗有效率为47.06%,RRM1表达阳性组中位TTP为67天,阴性组中位TTP为203天。结论晚期NSCLC组织中存在RRM1的表达,其表达和各临床特征无关。RRM1表达不同是晚期NSCLC患者对吉西他滨化疗敏感性存在差别的重要因素。

Objective： TO investigate the expression of RRM1 and the correlation with gemcitabine-based chemotherapy sensitivity in advanced non-small cell lung cancer（NSCLC）.Methods： From January 2005 to December 2008,51 cases were diagnosed by pathology and treated with gemcitabine-based chemotherapy in advanced non-small cell lung cancer.The expression of RRM1 was examined by immunohistochemical technique.To analyze the correlation expression of RRM1 with the curative effectin the near future and TTP,χ2test is used to compare the rate of sample, Kaplan-meier is used to one-way survival analysis TFP （Time to progression ） , Log-rank test the result. Results： In these 51cases, positive rate of RRM1 was 33.3% （ 17/51 ） , The response rate of gemcitabine-based chemotherapy in positive expression group was 17.65% , which in negative group was 47.06%. The medial TTP was 67 days in RRM1 expression positive group, which was 203 days in RRM1 expression negative group. Conclusion： The expression of RRMI situated in the advanced non-small cell lung cancer tissue. The expression had no relationship with clinical characteristics. The different expression of RRMI is a important factor to different Gemcitabiue-based chemothempy sensitivity in advanced NSCLC.